As RMJH-111b moves closer to clinical approval, what is the likelihood that the drug will be approved?
RMJH-111b is under clinical development by RMJ Holdings and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect RMJH-111b’s likelihood of approval (LoA) and phase transition for Idiopathic (Essential) Hypertension took place on 26 Sep 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RMJH-111b LoA and PTSR Report.
RMJH-111b overview
RMJH-111b is under development for the treatment of essential hypertension. It is administered as soft gelatin capsules through oral route. The drug candidate is developed based on inverted micellar technology.
RMJ Holdings overview
Quick View RMJH-111b LOA Data
| Report Segments | |
| Drug Name | |
| Administration Pathway | |
| Therapeutic Areas | |
| Key Developers | |
| Highest Development Stage |
Source link
#RMJH111b #moves #closer #clinical #approval #likelihood #drug #approved
